BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 31500785)

  • 21. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
    El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
    Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
    Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
    Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
    Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
    Yang X; Li Y; Ren XT; Fan L; Hua B
    World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Axillary Dissection with
    Munck F; Andersen IS; Vejborg I; Gerlach MK; Lanng C; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2023 Jul; 30(7):4135-4142. PubMed ID: 37062781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
    Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
    Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
    Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
    Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
    Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
    Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved False-Negative Rates with Intraoperative Identification of Clipped Nodes in Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.
    Cabıoğlu N; Karanlık H; Kangal D; Özkurt E; Öner G; Sezen F; Yılmaz R; Tükenmez M; Önder S; İğci A; Özmen V; Dinççağ A; Engin G; Müslümanoğlu M
    Ann Surg Oncol; 2018 Oct; 25(10):3030-3036. PubMed ID: 29978371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.
    Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L
    Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients Before Neoadjuvant Chemotherapy: A Preliminary Study.
    Kim EY; Byon WS; Lee KH; Yun JS; Park YL; Park CH; Youn IY; Choi SH; Choi YJ; Kook SH; Do SI
    World J Surg; 2018 Feb; 42(2):582-589. PubMed ID: 28808843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axillary lymph node dissection for patients with invasive breast cancer at Charlotte Maxeke and Chris Hani Baragwanath Academic Hospitals.
    Groenewald C; Cubasch H; Mannell A; Ayeni O; Nietz S
    S Afr J Surg; 2019 Dec; 57(4):18-24. PubMed ID: 31773927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
    Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
    Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.
    Laws A; Dillon K; Kelly BN; Kantor O; Hughes KS; Gadd MA; Smith BL; Lamb LR; Specht M
    Ann Surg Oncol; 2020 Nov; 27(12):4819-4827. PubMed ID: 32740737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.